Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $134.30 million
P/E Ratio 83.33
Dividend Yield 0.00%
Shares Outstanding 1.34 billion
Earnings per share 0.001
Dividend per share N/A
Year To Date Return -4.76%
Earnings Yield 1.20%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Alcidion Group Ltd (ASX: ALC)
    Latest News

    two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
    Growth Shares

    ASX shares: Invest in these 2 stocks for a legit chance at $1 million

    The key to achieving a $1 million portfolio is finding big compounding potential in small places...

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    Share Market News

    3 ASX All Ordinaries shares getting hammered on quarterly updates

    Monday has not been kind to these ASX All Ords shares...

    Read more »

    Two men cheering at laptop
    Opinions

    Skin in the game: The ASX share in my portfolio I'm most excited about

    Our Foolish writers spill the tea on the shares they own and have the highest hopes for.

    Read more »

    three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
    Small Cap Shares

    3 battered small-cap ASX shares we're still backing: expert

    Smaller businesses saw their valuations tumble in a troubled year like 2022, but will likely rocket up higher and faster…

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Market News

    Top fund manager thinks ASX could start to move decisively higher, potentially sooner than you might be expecting

    Two ASX small cap stocks with material upside potential.

    Read more »

    A happy woman holding an umbrella in front of a rainbow.
    Best Shares

    Top ASX shares to buy in September 2022

    These are the stocks our Foolish writers think could be set to blossom in spring.

    Read more »

    a man sits at his computer screen scrolling with his fingers with a satisfied smile on his face as though he is very content with the news he is receiving.
    Earnings Results

    3 ASX All Ords shares lifting on full-year results

    It's been a good day so far for these companies delivering their earnings results on Tuesday.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Alcidion, Betmakers, BrainChip, and Zip shares are racing higher

    These ASX shares are pushing higher on Wednesday...

    Read more »

    Five healthcare workers standing together and smiling.
    Technology Shares

    Alcidion share price surges 18% higher on record quarter

    Alcidion shares are on fire on Wednesday...

    Read more »

    A doctor and an elderly couple sit at a desk and look at a lung scan uploaded using Alcidion software as the Alcidion share price falls
    Ask a Fund Manager

    Buy and hold this 'incredibly undervalued' ASX share for 4 years: fundie

    Ask A Fund Manager: Cyan Investment Management's Dean Fergie is confused as to why this medical software business has been…

    Read more »

    A baby lying on a pile of one hundred dollar notes
    Small Cap Shares

    5 small-cap ASX shares sitting on a pile of cash: experts

    When interest rate fears bite, those who have their own money are king. Here are five such companies that Cyan…

    Read more »

    Two children hold on tightly to books hugged against their chests, as if they were holding on to ASX shares for the long term.
    Small Cap Shares

    2 ASX shares we're sticking with after 60% falls: fund managers

    Stock prices are now 'extremely attractive', say portfolio managers that are focusing on the long term for their small-cap fund.

    Read more »

    Frequently Asked Questions

    No, Alcidion does not pay dividends at this time.

    Alcidion listed on the ASX on 24 June 2011.

    ALC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Alcidion Group Ltd

    Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.

    The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.

    Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems.  Other products include Smartpage and Patientrack software.

    Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.

    ALC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Feb 2026 $0.10 $0.00 0.00% 822,194 $0.11 $0.11 $0.10
    16 Feb 2026 $0.10 $0.00 0.00% 180,973 $0.11 $0.11 $0.10
    13 Feb 2026 $0.10 $-0.01 -9.09% 906,957 $0.11 $0.11 $0.10
    12 Feb 2026 $0.11 $0.01 9.52% 2,502,208 $0.11 $0.11 $0.11
    11 Feb 2026 $0.11 $-0.01 -9.09% 738,810 $0.11 $0.11 $0.11
    10 Feb 2026 $0.11 $0.00 0.00% 132,914 $0.11 $0.11 $0.11
    09 Feb 2026 $0.11 $0.01 9.52% 836,848 $0.11 $0.11 $0.11
    06 Feb 2026 $0.11 $0.00 0.00% 4,267,442 $0.11 $0.11 $0.10
    05 Feb 2026 $0.11 $-0.01 -9.09% 665,736 $0.12 $0.12 $0.11
    04 Feb 2026 $0.11 $-0.01 -8.70% 1,257,487 $0.12 $0.12 $0.11
    03 Feb 2026 $0.12 $0.00 0.00% 1,096,297 $0.12 $0.12 $0.12
    02 Feb 2026 $0.12 $0.00 0.00% 1,581,896 $0.12 $0.12 $0.12
    30 Jan 2026 $0.12 $0.00 0.00% 703,019 $0.12 $0.13 $0.12
    29 Jan 2026 $0.12 $-0.01 -8.00% 893,081 $0.13 $0.13 $0.12
    28 Jan 2026 $0.13 $0.00 0.00% 999,224 $0.13 $0.13 $0.12
    27 Jan 2026 $0.13 $0.00 0.00% 2,009,550 $0.13 $0.13 $0.12
    23 Jan 2026 $0.13 $0.01 8.33% 1,201,002 $0.13 $0.13 $0.12
    22 Jan 2026 $0.12 $0.00 0.00% 1,266,815 $0.13 $0.13 $0.12
    21 Jan 2026 $0.12 $-0.01 -7.69% 2,533,444 $0.13 $0.13 $0.12
    20 Jan 2026 $0.13 $0.01 8.00% 10,803,008 $0.13 $0.14 $0.13

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    04 Mar 2025 Katrina (Kate) Doyle (Quirke) Sell 5,000,000 $425,000
    Off-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Jayne Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
    Ms Wilson is an experienced company director with private, ASX listed and not-for-profit organisations. In her previous executive career, she held global leadership roles in marketing communication, investor relations, and corporate affairs. She has experience in ESG stakeholder communication, issues, crisis and risk management, transactions, and investor relations. She has worked with multinational and growth companies in technology, healthcare, retail, and professional services sectors. Rebecca is experienced in leading companies during important commercial activation phases working with CEOs as both an advisor and non-executive director to develop and execute effective business strategy that supports accelerated and sustained growth. She's a Non-Executive Director of NFP, The Tomisich Foundation and Veski.
    Mr William (Bill) Smart Non-Executive Director Oct 2024
    Mr Smart is a global digital health leader with over 30 years of experience leading transformational change in organisations. Will has a track record of driving politically sensitive and operationally critical initiatives, enhancing organisational performance. Based in the United Kingdom, Will is currently Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust and was previously the CIO for Health and Social Care for England. In that role, Will provided advice to the Secretary of State for Health and Social Care and developed and delivered national strategies on information, technology and informatics. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. Until recently, Will served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of their European built Electronic Patient Record (EPR) solution into Ireland and the UK. He is member of the Risk Committee.
    Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Ms Doyle, since July 2018, has been the Group Managing Director and Chief Executive Officer of the Alcidion Group, a company dedicated to providing smart technology to the health sector. Kate leads the business globally with a goal of developing mutually beneficial relationships with customers, partners and investors. Kate has 25 plus years of digital health sector experience and has been involved in procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia. Her background includes management roles at healthcare software firms where she has driven strategic product direction, global sales and operations. She believes technology can enable the transformation of healthcare delivery. Kate is currently a Non-Executive Director of ANDHealth, Australia's provider of accelerator, incubator and commercialisation programs for digital health technology companies.
    Mr Daniel Sharp Non-Executive Director Sep 2021
    Mr Sharp originally commencing his career as a lawyer and has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Danny was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Danny headed the corporate finance division at two of Australia's independent Investment Banking/Stockbroking firms. Danny has managed the IPOs, capital raisings and corporate advisory activities for ASX listed companies in the healthcare, technologies and general industrials sectors. He is connected to strong networks of institutional, family office and investors both in Australia and overseas. Danny is currently Non-Executive Chair of VetScripts Pty Ltd and a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation. He is chair of the Risk Committee.
    Professor Andrew Way Non-Executive Director Apr 2025
    Mr Way commenced his career as a nurse in the UK National Health Service (NHS) and after a range of clinical positions, moved first into nursing leadership and then in the late 1980's into general management. Andrew has held several senior executive roles in research-focussed hospitals in both the UK NHS and Australia. He has been a Chief Executive for nearly 25 years, most recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through clinical and non-clinical digital transformations. Andrew is currently Board Chair of HealthShare Victoria and a Director of Australian College of Health Service Management (ACHSM). He was Interim CEO at the Royal Australian New Zealand College of Psychiatrists between December 2024 and July 2025. He continues to hold a range of other health related advisory roles. He is member of the Risk Committee.
    Mr Michael Sapountzis Company Secretary Mar 2019
    -
    Matthew Gepp Chief Financial Officer
    -
    Michael Sapountzis Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 209,178,732 15.58%
    Mr Malcolm Pradhan 116,416,160 8.67%
    Mr Raymond Howard Blight 68,664,657 5.11%
    Bond Street Custodians Limited <Salter D79836 A/C> 50,000,000 3.72%
    Mr Paul John Van Dyk 34,608,937 2.58%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 28,824,376 2.15%
    Rewmicman Pty Ltd <Smallman Family A/C> 27,266,938 2.03%
    Mrs Katrina Elizabeth Doyle 22,793,199 1.70%
    MNMD Pty Ltd <Quirke Super Fund A/C> 20,668,086 1.54%
    Caledonia Nominees Pty Ltd <Caledonia A/C> 19,976,377 1.49%
    Citicorp Nominees Pty Limited 15,222,342 1.13%
    Mr Dean Anthony Mackenzie 14,557,240 1.08%
    Sandhurst Trustees Ltd <Cyan C3G Fund A/C> 11,469,114 0.85%
    Ubs Nominees Pty Ltd 9,840,656 0.73%
    Netwealth Investments Limited <Wrap Services A/C> 8,050,478 0.60%
    Bond Street Custodians Limited <Rsalte D62375 A/C> 8,050,000 0.60%
    Rangiora London Pty Limited <Rangiora London A/C> 7,800,000 0.58%
    Emerald Shares Pty Limited <Emerald Unit A/C> 7,100,000 0.53%
    Mr Vivek Ramakrishnan and Miss Nisha Srinivasan 7,021,913 0.52%
    Mast Financial Pty Ltd <A To Z Investment A/C> 6,425,000 0.48%

    Profile

    since

    Note